Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1Phase 1 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Gastrointestinal 1

Conditions

Prostatic Neoplasms 1Primary Dysautonomias 1Pancreatic Neoplasms 1Neoplasms 1Kidney Diseases 1Hypertension 1High Risk Prostate Cancer 1

Interventions

Cyclophosphamide 3162Cisplatin 3160Carboplatin 2938Paclitaxel 2673Radiotherapy 2648Gemcitabine 2547pembrolizumab 2331Docetaxel 2157Bevacizumab 2128Fluorouracil 1822Capecitabine 1784Oxaliplatin 1713Dexamethasone 1590Nivolumab 1517Doxorubicin 1477Rituximab 1454Etoposide 1342Magnetic Resonance Spectroscopy 1266Irinotecan 1235Leucovorin 1216Cytarabine 1123Pemetrexed 1062Drug Therapy 1062fludarabine 1050Vincristine 956Specimen Handling 936Prednisone 926Cetuximab 921Lenalidomide 916Trastuzumab 902

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Receptors, Androgen × Clear all
NCT05700903 2026-03-02

ARCH

University of Colorado, Denver

Phase 4 Completed
10 enrolled
Genitourinary

Hypertension, Kidney Diseases, Prostatic Neoplasms, Primary Dysautonomias

NCT06758882 2025-01-06

STAPLE

A.O.U. Città della Salute e della Scienza

Phase 2 Recruiting
94 enrolled
Genitourinary

High Risk Prostate Cancer

NCT02138383 2021-08-17

Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
25 enrolled
Gastrointestinal

Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡